Pixium Vision Past Earnings Performance

Past criteria checks 0/6

Pixium Vision has been growing earnings at an average annual rate of 3.8%, while the Medical Equipment industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 0.2% per year.

Key information

3.8%

Earnings growth rate

32.7%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate0.2%
Return on equityn/a
Net Margin-584.7%
Last Earnings Update30 Jun 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Pixium Vision makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:PXMV.F Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 232-1149
31 Mar 232-1059
31 Dec 222-1059
30 Sep 222-1158
30 Jun 222-1168
31 Mar 222-1167
31 Dec 212-1167
30 Sep 212-1167
30 Jun 212-1167
31 Mar 212-1056
31 Dec 202-946
30 Sep 202-946
30 Jun 202-846
31 Mar 202-946
31 Dec 192-1047
30 Sep 192-1347
30 Jun 192-1647
31 Mar 192-1536
31 Dec 182-1335
30 Sep 182-1236
30 Jun 182-1046
31 Mar 182-1257
31 Dec 173-1467
30 Sep 172-1368
30 Jun 172-1268
31 Mar 172-1259
31 Dec 163-12510
30 Sep 163-14611
30 Jun 163-15612
31 Mar 163-15613
31 Dec 153-16514
30 Sep 153-15514
30 Jun 153-15513
31 Mar 153-13412
31 Dec 142-12411
30 Sep 142-10310
30 Jun 142-829
31 Mar 142-718
31 Dec 131-616
31 Dec 120-310

Quality Earnings: PXMV.F is currently unprofitable.

Growing Profit Margin: PXMV.F is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PXMV.F is unprofitable, but has reduced losses over the past 5 years at a rate of 3.8% per year.

Accelerating Growth: Unable to compare PXMV.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PXMV.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (3.7%).


Return on Equity

High ROE: PXMV.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/11/27 21:00
End of Day Share Price 2023/08/30 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pixium Vision SA is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBrookline Capital Markets
Hugo SolvetBryan Garnier & Co
Pooya HemamiEdison Investment Research